Targeting Iatrogenic Cushing's Syndrome With 11 β-hydroxysteroid Dehydrogenase Type 1 Inhibition
Condition: Iatrogenic Cushing's Disease Interventions: Drug: AZD4017 and prednisolone; Drug: Placebo Oral Tablet and prednisolone Sponsors: University of Oxford; AstraZeneca Not yet recruiting - verified April 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 17, 2017 Category: Research Source Type: clinical trials